As always, it was an honor to speak with Prof. John E Harris (University of Massachusetts Medical School, Worcester, MA, USA) about therapies, old and new, that have been used in the treatment of vitiligo.
His presentation entitled ‘Vitiligo: from topical JAK inhibitors to anti-IL15R’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021.
- Could you give us a brief overview of vitiligo, its prevalence and its association with other autoimmune diseases? (0:12)
- How do newer treatments compare to traditional autoimmune therapies? (0:57)
Disclosures: Prof. John E Harris has acted as a consultant and investigator for Pfizer, Genzyme/ Sanofi, Incyte, Rheos Medicines, Sun Pharmaceutical, LEO Pharma, Villaris Therapeutics, Dermavant and TeVido BioDevices; a consultant for AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, NIRA Biosciences, Admirx, Granular Therapeutics and Platelet BioGenesis; has Equity in TeVido Biodevices, Rheos, Villaris Therapeutics, NIRA Biosciences and is Founder of Villaris Therapeutics and NIRA Biosciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickleson.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
Share this Video
Related Videos In Vitiligo
Amit G. Pandya, Dermatology Meeting News 2023: Efficacy & safety of ruxolitinib cream in vitiligo – findings from the TRuE-V phase 3 studies
TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies that investigated ruxolinitib cream for the treatment of vitiligo over 52 weeks. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) around the efficacy and safety findings from the TRuE-V phase 3 studies and […]
Amit G. Pandya, Dermatology Meeting News 2023: JAK inhibitors for the treatment of vitiligo
Ruxolitinib cream, a cream formulation of the JAK 1/JAK2 inhibitor was first approved for use in vitiligo by the FDA in July 2022 and is the only topical treatment approved for repigmentation. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) around the rationale and adverse […]
Thierry Passeron, EADV 2022: Efficacy of Ruxolitinib Cream by Body Region in Vitiligo – A Pooled Analysis of the TRuE-V Phase 3 Studies
TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies investigating ruxolitinib cream in adults and adolescents with vitiligo. touchIMMUNOLOGY were delighted to speak with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the rationale and findings from his pooled analysis looking at the effect of ruxolitinib cream on achievement […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!